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Background: The purpose of the present study was to evaluate the prognostic value of POSTN expression
following prostatectomy.
Methods: Periostin (POSTN) expression in prostate cancer (PCa) and in normal specimens was evaluated in 90
patients by an immuno-reactive score(IRS) based on the intensity of immunostaining and on the quantity of stained
cells. The t-test was applied to compare IRS values in cancer specimens to values in normal specimens. Pearson’s
test was used to correlate POSTN expression to clinical pathologic features. PSA progression-free and survival curves
were constructed by the Kaplan–Meier method and compared using the log-rank test. Multi-parametric models
were constructed according to the Cox technique adding all the covariates predicting for either PSA progression or
death into the models after univariate analysis.
Results: Both stromal and epithelial POSTN expression were significantly increased in tumor tissues. In particular,
we found stromal expression to be significantly higher than epithelial expression as compared to normal tissues
(p<0.000 and p=0.001).A significant correlation between POSTN epithelial expression and extra-prostatic extension
was found (p=0.03). While high stromal expression was significantly associated with shorter survival (p=0.008), a low
epithelial score significantly correlated with shorter PSA-free survival (p=0.04), suggesting that POSTN plays an
apparently opposing biological role depending on its compartmentalization.Regardless of the mechanism that is
involved, patients showing both high stromal and low epithelial expression made up a subgroup with a very bleak
prognosis.
Conclusions: Although requiring further validation through larger studies, our findings show that POSTN might
represent a novel prognostic marker for PCa.
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Prostate cancer (PCa) has become the most common ma-
lignancy among men in most Western countries [1]. Even
when this tumor is apparently confined to the prostate, it
encompasses a broad spectrum of diseases, some of which
are characterized by extremely indolent behavior and others
by very poor outcome. Therefore, an important clinical
question is how aggressively to treat patients diagnosed at
this stage. Among patients who are treated with radical
prostatectomy, the most commonly used parameters for
defining prognosis and choosing the right candidates for
adjuvant local irradiation or systemic treatments include
tumor volume and pathological grade and status of surgical
margins, seminal vesicles and pelvic nodes [2]. However,
there is no widely accepted method for quantifying tumor
volume [3]. Moreover, tumor grade scoring methods can
result in significant inter-observer variations, particularly
when defining intermediate tumor grades [4,5]. This applies
specifically to the old Gleason scoring method. New prog-
nostic markers are therefore required.
Many of the cellular abnormalities that are present in
most solid tumors are structural in nature and involve
either the nuclear matrix (NM) or the extracellular matrix
(ECM), both of which are regarded as a promising source
of new markers [6-8]. Among the components of ECM,
increasing interest has been shown in Periostin (POSTN), a
protein produced by fibroblasts, as a major putative player
in human carcinogenesis [8]. During embryogenesis, this
protein is preferentially expressed in the periosteum and
periodontal ligaments where it acts as a critical regulator of
bone and tooth formation and maintenance [9]. However, it
was also shown to play an important role in cardiac devel-
opment [10]. In adults, POSTN is up-regulated by mechan-
ical stress and contributes to tissue repair and regeneration
[11,12]. It has recently been suggested that POSTN might
also play a relevant role in human carcinogenesis. In fact,
this protein interacts with multiple cell-surface receptors,
most notably integrins, as well as with signals mainly via
the PI3-K/Akt and other pathways, thus promoting cancer
cell survival, epithelial–mesenchymal transition (EMT), in-
vasion, and metastasis [13]. Though it is currently not clear
whether the production and secretion of POSTN is directly
mediated by tumor epithelial cells or by stromal cells, or by
both, overexpression of POSTN in cancer stroma and/or in
the epithelium is usually associated with the most ma-
lignant phenotypes and with poor clinical outcome [8]. In
bladder cancer however, protein down-regulation was
shown to be associated with poorer prognostic features
[14], suggesting that POSTN can act either as a tumor
promoter or as a tumor suppressor gene, most likely
depending on several variables, including the protein
isoform and /or the interactor involved in the process.
To the best of our knowledge, to date only two studies
have investigated the clinical relevance of POSTNoverexpression in PCa [15,16]. In one study, increased
epithelial expression was found during the early stages
of PCa, whereas stromal POSTN expression prevailed
in advanced stages [15]. In the other study, which also
showed POSTN to be far more overexpressed in tumor
tissues than in peritumoral tissues, POSTN appeared to
be overexpressed both by the epithelial and by the
stromal cells [16]. In this study, a strong association
between epithelial expression and local tumor stage was
observed, while stromal overexpression appeared to be
correlated mainly with a high Gleason score and an
increased risk of biochemical failure [16].
In the present study we investigated POSTN expres-
sion in PCa tissue specimens and in normal peritumoral
specimens in order to confirm previous findings and to
evaluate the putative prognostic value of POSTN also as
a function of its compartmentalization.
Methods
Patient selection
Since we originally planned to study POSTN overexpres-
sion in cryopreserved material by immune blotting techni-
ques, a patient cohort we had previously utilized for
studies on NM proteins was selected [7]. This cohort is
made up of 90 patients who underwent radical prostatec-
tomy for biopsy proven PCa between October 1995 and
October 2003, and who were subsequently referred to our
Unit for treatment or follow-up. Before surgery, all patients
had provided consent allowing tumor tissue specimens to
be collected for proteomic analysis. This research project
was approved by the Ethical Committee of the National
Cancer Research Institute of Genoa, Italy. Unfortunately,
most of the stored material had been used for previous
studies on NM proteins and therefore large enough sam-
ples for the present evaluations were no longer available.
This prompted us to retrieve corresponding archival mater-
ial in order to allow us to carry out immune histochemical
studies. We were able to follow-up most of our cohort
patients at regular intervals. However, over time, a relevant
number of patients failed to attend clinical examinations,
so the vital status of these patients had to be checked by
phone, or, when this was not possible, by contacting the
local tumor registry or the registry office of the patient’s
place of residence. The main characteristics of the patients
making up the study cohort are summarized in Table 1.
Immunohistochemistry (IHC)
IHC analysis was carried out using 3-μm sections of paraf-
fin embedded prostate tissue using the POSTN (OSF-2)
Polyclonal Antibody (Acris Antibodies, Germany; Host/
Isotype:Rabbit), suitable for various isoforms of POSTN.
The antibody was diluted at 1:500.
The most representative tumor and normal peritu-
moral tissue sections were immunostained using the
Table 1 Main characteristic of study patients
Total patients
N=90(%)
Median age in years(range) 64(48–77)
Median PSA level at surgery in ng/ml(range) 11.0(1.7-167.4)
Extra-prostatic extension 46(51.1)
Pelvic nodes involved 16(17.8)
Surgical margins involved 34(37.8)
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Systems, SA Stasbourg, France). Slides were deparaffi-
nized, and after adding high Ph, heat induced, standard cit-
rate buffer (30 min), the antibody-antigen complex was
relieved using the polymeric detection system (Ventana
Medical System Ultraview Universal DAB Detection Kit).Figure 1 POSTN expression in tumor stroma: tumor specimens gradeA negative and a positive control were used for each stain-
ing run. The negative control consisted of performing the
entire IHC procedure on adjacent sections in the absence
of the primary antibody. Then the sections were counter-
stained with Gill's modified hematoxylin, cover-slipped and
evaluated by two different observers using an Olympus
multi-headed light microscope using 10X, 40X and 63X
magnifications.
Evaluation of staining
To evaluate epithelial and stromal POSTN expression,
we used the immuno-reactive score (IRS) as previously
implemented by Tischler et al. [16], based on the inten-
sity of immune staining and the quantity of stained cells.
The intensity of staining was arbitrarily graded as: absent
(0), weak (1+), moderate (2+), strong (3+). The percen-
tage of stained cells was used to quantify the reaction as
negative (0% of positive cells), 1+ (<10% positive cells);
2+ (10-50% of positive cells); 3+ (51-80% of positive
cells); 4+ (>80% of positive cells). The final value of the
analysis of each tissue sample was then expressed as and 0 to 3+ according to arbitrary scoring (see text) are shown.
Figure 2 POSTN expression in tumor epithelium: tumor specimens graded 0 to 3+ according to arbitrary scoring (see text) are shown.
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the two individual scores (i.e., intensity of staining score
times the percentage of stained cells score). Examples of
scoring according to staining intensity and the percen-
tage of stained cells are shown in Figures 1 and 2.
Main analysis endpoints
PSA progression-free survival and overall survival were the





Tumor tissue:%Cells stained 0.89(0.13)
Normal tissue:%Cells stained 0.41(0.09)
Tumor tissue:IRS 1.24(0.21)
Normal tissue:IRS 0.46(0.10)
Abbreviations:SE,Standard Error;IRS, Immuno-reactive score.was defined by any PSA serum level of 0.4 ng/ml or more
following prostatectomy, provided that this value had been
confirmed at least once, and at least 4 weeks apart. PSA
progression-free survival was thus defined by the amount
of time that elapsed from the date the patient underwent
prostatectomy to the date of the documented PSA progres-
sion as defined above. Overall survival was calculated as the
amount of time between the date of prostatectomy and the
date of death, regardless of the cause.r normal tissue specimens
Stroma







Figure 3 PSA progression-free Survival (A) and Overall Survival (B) as a function of stromal IRS (see text for explanations).
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The t-test was applied to compare mean values (Standard
Error: SE) of stromal or epithelial IRS in PCa tissue spe-
cimens with those calculated in normal peritumoral tissue
specimens. Pearson’s correlation was used to correlate
either epithelial or stromal POSTN expression with all of
the following: PSA, Gleason score, extra-prostatic exten-
sion, lymph node status, involvement of surgical margins or
of seminal vesicles. PSA progression-free and overallFigure 4 PSA progression-free (A) and Overall Survival (B) as a functiosurvival curves were constructed by the Kaplan–Meier
method [17] and compared using the log-rank test [18]. To
evaluate the role of prognostic variables, a series of Cox
proportional hazards models were fitted to PSA
progression-free and overall survival data [19]. The follow-
ing covariates were included in all models: pre-surgery
PSA levels (<=10 ng/ml, >10 ng/ml); extra-prostatic exten-
sion (Yes, No); involvement of surgical margins (No, Yes);
involvement of seminal vesicles (No, Yes); Gleason scoren of epithelial IRS (see text for explanations).
Table 3 Multivariate analysis
PSA Progression-Free Survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 1.41 (0.67-2.97) 0.4 1.26 (0.59-2.68) 0.5 1.30 (0.61-2.79) 0.5
Extra-prostatic extension
Yes 1.0 1.0 1.0
No 3.33 (1.31-8.49) 0.01 3.21 (1.28-8.07) 0.01 3.21 (1.27-8.09) 0.01
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.56 (0.69-3.56) 0.3 1.38 (0.60-3.14) 0.4 1.40 (0.61-3.18) 0.4
Surgical margins involved
No 1.0 1.0 1.0
Yes 0.75 (0.31-1.79) 0.5 0.72 (0.31-1.67) 0.4 0.68 (0.29-1.62) 0.4
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 0.77 (0.35-1.68) 0.5 0.64 (0.28-1.43) 0.3 0.64 (0.28-1.42) 0.3
Gleason score
<7 1.0
≥7 2.03 (0.91-4.55) 0.08
Gleason score
≤7 1.0
>7 3.29 (1.63-6.65) 0.001
Gleason score
<7 1.0 0.003
=7 1.33 (0.54-3.26) 0.5
>7 3.90 (1.59-9.55) 0.003
Epithelial IRS
>2 1.0 1.0 1.0
≤2 6.20 (1.30-29.44) 0.02 4.85 (0.98-24.09) 0.05 4.86 (0.98-24.05) 0.05
Stroma IRS
<12 1.0 1.0 1.0
=12 2.06 (0.87-4.88) 0.1 1.90 (0.77-4.65) 0.1 1.84 (0.76-4.50) 0.6
Abbreviations:HR, Hazard Ratio;CI,Confidence Interval;PSA,Prostate-specific antigen;IRS,Immuno-reactive score.
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>7); involvement of pelvic nodes (N0, N+); epithelial IRS;
stromal IRS and stromal plus epithelial IRS. Relative to
IRS, the value corresponding to the 75th percentile was
used as an arbitrary cut-off (75th percentile value of epithe-
lial IRS=2; 75th percentile value of stromal IRS=12). The
75th percentile value was infact the value which better dis-
criminated the patient-cohort according to the main clin-
ical outcome endpoints on study.
A stepwise procedure was used with a significance level
of p=0.05 to retain variables in the model. Hazard Ratio(HR) estimates and their 95% Confidence Intervals (CIs)
were also calculated [18]. All P values were two-tailed. The
IBM software Statistical Package for Social Sciences (SPSS)
version 19.0 for Windows (SPSS Inc. Chicago, Illinois,
USA) was used for data analysis.
Results
POSTN expression in the epithelium and stroma of
prostate tissues
Distinct stromal and epithelial staining characteristics
allowed for absolutely certain evaluation of POSTN
Table 4 Multivariate analysis
Overall survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 0.54 (0.15-2.03) 0.4 0.48 (0.12-1.86) 0.3 0.48 (0.12-1.87) 0.3
Extra-prostatic extension
Yes 1.0 1.0 (0.76-17.35) 1.0
No 3.43 (0.73-16.12) 0.1 3.63 0.1 3.48 (0.73-16.54) 0.1
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.71 (0.50-5.79) 0.4 1.44 (0.43-4.83) 0.5 1.40 (0.42-4.72) 0.6
Surgical margins involved
No 1.0 1.0 1.0
Yes 1.37 (0.45-4.21) 0.6 1.38 (0.47-4.01) 0.6 1.33 (0.45-3.92) 0.6
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 1.39 (0.49-3.94) 0.5 1.08 (0.37-3.10) 0.9 1.11 (0.38-3.25) 0.8
Gleason score
<7 1.0
≥7 2.13 (0.55-8.19) 0.3
Gleason score
≤7 1.0
>7 2.80 (0.93-8.47) 0.07
Gleason score
<7 1.0 0.1
=7 1.43 (0.32-6.40) 0.6
>7 3.52 (0.79-15.61) 0.1
Epithelial IRS
>2 1.0 1.0 1.0
≤2 3.22 (0.56-18.48) 0.2 3.09 (0.51-18.63) 0.2 3.19 (0.52-19.47) 0.2
Stroma IRS
<12 1.0 1.0 1.0
=12 5.85 (1.82-18.77) 0.003 5.76 (1.84-18.07) 0.003 5.99 (1.87-19.22) 0.003
Abbreviations:HR,Hazard Ratio;CI Confidence Interval;PSA,Prostate-specific antigen;IRS Immuno-reactive score.
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cimens. Of the 90 prostate cancers, 79 (87.8%) dis-
played moderate (N°=32) or strong (N°=47) stromal
POSTN expression. The mean (SE) overall IRS value
was 6.37 (0.39). The expression of POSTN by tumor
epithelial cells was significantly lower than what was
observed in stromal cells (p=0.003). In fact, only 36
out of 90 (40%) cancer specimens showed weak
(N°=25) or moderate (N°=11) staining intensity. The
mean (ES) overall IRS in this case was 1.24 (0.21).
Notably, stromal POSTN expression significantlycorrelated with epithelial POSTN expression (p<0.000).
As shown in Table 2, both stromal and epithelial
POSTN expressions were significantly increased in
tumor tissues as compared to normal adjacent tissues
(p<0.000 and p=0.001, respectively). Nevertheless,
POSTN expression in the stromal component of nor-
mal tissues was about twice as high as what was
observed in the epithelial component of prostate can-
cer tissues (p=0.003), indicating that stromal cells
mostly contribute to POSTN secretion both in normal
and in neoplastic conditions.
Figure 5 PSA progression-free (A) and Overall Survival (B) as a function of both stromal and epithelial IRS (see text for explanations).
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We found no specific correlation between epithelial or
stromal POSTN expression and any of the clinical-
pathological parameters (PSA preoperative level; Gleason
score; extra-prostatic extension; lymph node status; in-
volvement of surgical margins or seminal vesicles) that we
evaluated in the present analysis except for a weak positive
correlation between POSTN stromal expression and
Gleason score (p=0.08), and a significant correlation be-
tween epithelial expression of the protein and extra-
prostatic extension (p=0.03).Correlation of POSTN expression with PSA-free and
overall survival
After a median follow-up time of 134.5 months (range,
33.7–178.2), 44 patients progressed and 19 died. Median
time to PSA progression for the whole cohort was 94.5
months (range 3–169.6), while median time to death has
not been reached yet. POSTN expression in the stromal
and epithelial compartments of the tumor both correlated
with PSA progression-free survival or overall survival, al-
beit in a different manner. Stromal POSTN expression
was significantly associated with overall survival, for an
IRS value of 12, corresponding to the 75th percentile. The
group of patients with an IRS=12 (strong staining intensity
and 80% of positive cells) showed significantly shorter sur-
vival than patients with an IRS<12 (p=0.008). These
patients also showed a trend for shorter PSA-free survival
(Figure 3). While no significant correlation was found be-
tween epithelial IRS and patients' survival, in contrast to
previous findings, a higher epithelial score (IRS>2, againcorresponding to the 75th percentile) was significantly
correlated with longer PSA-free survival (p=0.04)
(Figure 4). Since stromal and epithelial expression
appeared to have different correlations despite being dir-
ectly correlated to each other as previously mentioned, the
two variables (i.e., stromal and epithelial POSTN scores)
were both included in the same multiparametric models
together with the other variables that predicted both
PSA–free and overall survival in univariate analysis. Differ-
ent models were created on the basis of the Gleason score
(Tables 3 and 4). Multivariate analysis confirmed that epi-
thelial expression independently correlated with the risk
of PSA progression, regardless of how the Gleason score
was analyzed. Low expression did in fact imply an increase
in the risk of PSA failure, which became statistically sig-
nificant when the Gleason score was analyzed by arbitrar-
ily grouping patients with a score >7 with those showing a
score equal to 7. Multivariate analysis also confirmed that
stromal IRS did not predict the risk of PSA failure, regard-
less of which Gleason score variable was used. By contrast,
stromal IRS was the only independent predictor of the risk
of death, regardless of how the Gleason score variable was
analyzed. Epithelial IRS was not predictive of the risk of
death, similarly to all the other variables we considered,
including extra-prostatic extension and Gleason score.
However, the latter variables were predictors of the risk of
PSA failure. Noteworthy, the patients showing both high
stromal expression (IRS=12) and low epithelial expression
(IRS<=2) made up a subgroup with a very bleak prognosis,
showing both the shortest PSA-free (p=0.005) and the
shortest overall survival (p=0.02) (Figure 5).This trend was
confirmed by multivariate analysis (Tables 5 and 6).
Table 5 Multivariate analysis
PSA Progression-Free Survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 1.39 (0.66-2.96) 0.4 1.25 (0.58-2.68) 0.6 1.29 (0.60-2.78) 0.5
Extra-prostatic extension
Yes 1.0 1.0 1.0
No 3.30 (1.29-8.47) 0.01 3.21 (1.27-8.07) 0.01 3.20 (1.27-8.09) 0.01
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.55 (0.68-3.55) 0.3 1.37 (0.60-3.14) 0.4 1.39 (0.61-3.18) 0.4
Surgical margins involved
No 1.0 1.0 1.0
Yes 0.75 (0.31-1.81) 0.5 0.72 (0.31-1.67) 0.4 0.68 (0.29-1.62) 0.4
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 0.77 (0.35-1.70) 0.5 0.64 (0.28-1.44) 0.3 0.64 (0.28-1.43) 0.3
Gleason score
<7 1.0
≥7 2.02 (0.90-4.54) 0.09
Gleason score
≤7 1.0
>7 3.29 (1.62-6.65) 0.001
Gleason score
<7 1.0 0.03
=7 1.32 (0.54-3.26) 0.5
>7 3.89 (1.58-9.54) 0.003
Stromal -Epithelial IRS Score
=12/≤2 1.0 0.08 1.0 0.2 1.0 0.2
<12/≤2 0.47 (0.19-1.17) 0.1 0.52 (0.20-1.33) 0.2 0.53 (0.21-1.37) 0.2
=12/>2 0.14 (0.01-1.33) 0.09 0.19 (0.02-1.89) 0.2 0.19 (0.02-1.89) 0.2
<12/>2 0.09 (0.01-0.77) 0.03 0.11 (0.01-1.10) 0.06 0.12 (0.01-1.11) 0.06
Abbreviations:HR,Hazard Ratio;CI ,Confidence Interval; PSA,Prostate-specific antigen;IRS, Immuno-reactive score.
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Comparably to previous findings by Tischler et al. [16],
we have demonstrated that POSTN is far more highly
expressed in cancer tissues than in normal tissues. In
our study, POSTN appears to be expressed mainly in the
stromal compartment, both in normal and in cancerous
tissues. In Tischler’s study, epithelial expression was
higher in normal tissues, while in cancerous tissues it
was higher in the larger test cohort, but it was lower in
the smaller training cohort [16]. Tischler's findings on
normal prostate gland tissues are comparable with those
previously reported by Tsunoda et al. [15] who alsofound higher POSTN expression in normal epithelial
cells. However, in this study, POSTN expression was also
higher in the epithelium than in the stroma of cancerous
tissues [15]. It is not easy to explain the differences that
were observed in the three studies. Besides the number
of patients and disease stage, these studies differ in some
methodological aspects. In our own, as well as in Tischler’s
study [16], POSTN detection was performed using the
same rabbit polyclonal antibody capable of recognizing all
the different POSTN isoforms. A polyclonal anti-POSTN
antibody was also used by the Japanese investigators for
their IHC determinations [15]. However, there were major
Table 6 Multivariate analysis
Overall survival
Model 1 Model 2 Model 3
HR (95%CI) p= HR (95%CI) p= HR (95%CI) p=
PSA,ng/ml
≤10ng/ml 1.0 1.0 1.0
>10ng/ml 0.49 (0.13-1.83) 0.3 0.45 (0.12-1.74) 0.2 0.45 (0.12-1.74) 0.2
Extra-prostatic extension
Yes 1.0 1.0 1.0
No 3.34 (0.71-15.66) 0.1 3.75 (0.79-17.88) 0.1 3.52 (0.74-16.77) 0.1
Pelvic nodes involved
N0 1.0 1.0 1.0
N+ 1.72 (0.50-5.88) 0.4 1.45 (0.43-4.93) 0.5 1.41 (0.41-4.79) 0.6
Surgical margins involved
No 1.0 1.0 1.0
Yes 1.42 (0.46-4.38) 0.5 1.36 (0.46-3.99) 0.6 1.31 (0.44-3.89) 0.6
Seminal vesicles involved
No 1.0 1.0 1.0
Yes 1.41 (0.50-3.97) 0.5 1.06 (0.37-3.05) 0.9 1.12 (0.38-3.20) 0.8
Gleason score
<7 1.0
≥7 2.19 (0.56-8.62) 0.3
Gleason score
≤7 1.0
>7 2.75 (0.90-8.42) 0.08
Gleason score
<7 1.0 0.2
=7 1.49 (0.33-6.81) 0.6
>7 3.56 (0.78-16.20) 0.1
Stromal -Epithelial IRS Score
=12/≤2 1.0 0.01 1.0 0.01 1.0 0.01
<12/≤2 0.13 (0.04-0.44) 0.001 0.14 (0.04-0.46) 0.001 0.14 (0.04-0.45) 0.001
=12/>2 0.19 (0.02-1.37) 0.1 0.21 (0.03-1.58) 0.1 0.20 (0.02-1.53) 0.1
<12/>2 0.12 (0.01-1.32) 0.08 0.12 (0.01-1.43) 0.09 0.11 (0.01-1.37) 0.09
Abbreviations:HR,Hazard Ratio;CI ,Confidence Interval; PSA, Prostate-specific antigen;IRS,Immuno-reactive score.
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Tischler used an immune score (IRS) obtained by mul-
tiplying the intensity of staining by the percentage of
stained cells. Notably, comparable median IRS values were
obtained by us and by the Swiss colleagues. However, the
results obtained in our two studies are not comparable
since patients were analyzed after arbitrarily grouping
them in different manners. In fact, in the Swiss study,
median IRS values were used as cut-off points to
dichotomize the tumors into a “POSTN low” and
“POSTN high” population, while we found that the cut
off score that best defined patient risk was the 75th per-
centile. In Tsunoda's study [15], IHC analysis only tookinto consideration the quantitative expression of POSTN
(positive: at least >5% of staining cells), without evaluating
staining intensity.
The differences in how patients were grouped,
i.e. according to their IRS, may have been particularly
relevant when POSTN expression was correlated with
clinical outcome.
Tischler’s study [16] evaluated the correlation between
POSTN expression and PSA relapse- free survival. They
showed that higher stromal POSTN was significantly
associated with shorter PSA-free survival both in the
training cohort and in the test cohort set. However, the
difference between low and high POSTN subgroups was
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might reflect the different size of the two cohorts and/or
the length of follow-up (45 vs 72 months, respectively).
However, it might also be associated with the different
characteristics of the two study populations. In fact, 46%
of the patients making up the training set showed bio-
chemical failure compared with 20% of those forming
the validation set. No relationship between PSA-free sur-
vival and epithelial POSTN expression was reported
in this study. Unfortunately, these investigators did not
explain the criteria that were adopted to define PSA pro-
gression, nor did they attempt to correlate POSTN
expression with patients' survival.
We also observed a direct relationship between stromal
POSTN IRS and PSA-free survival, however the difference
was not statistically significant, exactly as reported by
Tischler et al. [16] in their validation set which was much
larger than our own set but showed a comparable clinical
outcome. However, low epithelial POSTN expression was
associated with shorter PSA-free survival in our study,
and epithelial expression was not predictive of patient sur-
vival. By contrast, stromal expression was highly predictive
of the risk of death, while it was only a weak predictor of
PSA progression. These findings suggest that POSTN
might play a different biological role in tumor progression,
depending on its compartmentalization. In fact, while
POSTN down-regulation in PCa epithelium appears to be
correlated with extra-prostatic extension and biochemical
failure, both of which represent early events in the natural
history of the disease, POSTN overexpression in the
stroma appears to be highly predictive of the risk of death,
a late event that usually follows distant spreading and the
loss of hormone dependency. This differential effect has
been confirmed by multivariate analysis and suggests that
it may be possible to identify different tumor phenotypes
which are characterized by an increasing risk of PSA fai-
lure and death. In this regard, it is certainly intriguing that
the prognostic value of POSTN overexpression in stroma
is especially evident in patients whose tumors down-
regulate POSTN expression in the epithelial compart-
ment, but not in those whose tumors also overexpress the
protein in the epithelial component (Figure 5). The
phenotype characterized by low POSTN expression in the
epithelium and high protein expression in the stroma
showed a bleak prognosis, both in terms of PSA-free and
overall survival.
Moreover, multi-parametric models showed that the
proteomic signature based on the epithelial and stromal
expression of POSTN indeed added to the prognostic
information provided by the currently available variables,
including the Gleason score. It should be stated in
this regard that the old Gleason grading system was
used and that caution is therefore warranted in data
interpretation.Conclusions
Our findings should be regarded as merely exploratory and,
as such, they should be evaluated with caution. Nonethe-
less, they warrant IHC methodological standardization and
further validation of the potential usefulness of POSTN as
a prognostic marker in larger prospective series.
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